Comparative Pharmacology
Head-to-head clinical analysis: CURRETAB versus GYNOREST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CURRETAB versus GYNOREST.
CURRETAB vs GYNOREST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory changes in endometrium, inhibits pituitary gonadotropin secretion, and has anti-estrogenic effects.
Gynorest (dydrogesterone) is a synthetic progestogen that binds to the progesterone receptor with high selectivity, inducing conformational changes that promote transcription of progesterone-responsive genes. It has no androgenic, estrogenic, or corticosteroid activity, and does not inhibit ovulation.
5 mg orally once daily for 10 consecutive days per cycle, beginning on day 16 of the menstrual cycle.
100 mg orally twice daily for 5-10 days or 300 mg orally once daily for 6-12 days.
None Documented
None Documented
Terminal elimination half-life of medroxyprogesterone acetate (MPA) is approximately 12-17 hours (mean ~14 h) for oral administration; with intramuscular depot, half-life extends to ~6-7 weeks due to slow absorption from injection site
Terminal elimination half-life is approximately 16-20 hours; supports twice-daily dosing for maintenance of therapeutic levels.
Primarily renal (60-70% as metabolites, <10% unchanged); biliary/fecal (20-30%)
Renal: 50-80% as metabolites; Fecal: 20-50% as metabolites; Biliary excretion contributes to fecal elimination.
Category C
Category C
Progestin
Progestin